Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Lacosamide Demonstrates Strong Potential for Management of Diabetic Neuropathic Pain: Presented at APS

        By Elizabeth Nicholas

        SAN ANTONIO, T.X. -- May 5, 2006 -- New data from a phase 3 trial show that the primary end point for the lacosamide target dose reached a statistical significance level when the investigational compound was tested as a treatment for patients with painful diabetic neuropathy.

        Lacosamide, formerly known as SPM 927, is being studied as an anticonvulsant with potential for reducing diabetic neuropathic pain.

        The results were reported here on May 5th at the 25th Annual Meeting of the American Pain Society (APS).

        Aziz Shaibani, MD, director, Nerve and Muscle Center of Texas, Houston, Texas, and colleagues randomized 469 patients with pain secondary to distal diabetic neuropathy to a maximum of 20 weeks of twice-daily oral lacosamide or placebo across 4 different treatment arms in a 1:2:2:2 ratio, respectively: placebo; lacosamide 200 mg/day; lacosamide 400 mg/day; and lacosamide 600 mg/day.

        At enrollment, all subjects had an average daily pain score of 4 or greater on an 11-point Likert scale, a validated pain discomfort measure in which a score of 0 refers to no pain and 10 denotes unbearable pain.

        The treatment groups were similar with respect to gender, age, and body mass index.

        The primary efficacy variable was the within-subject change in the average daily Likert pain score from baseline to the last 4 weeks of the 12-week maintenance phase.

        The results show that the target lacosamide dose of 400 mg/day approached statistical significance (P =.0507). Lacosamide at 400 mg and 600 mg lowered pain scores significantly throughout the treatment and maintenance periods.

        The 200 mg and 400 mg doses were better tolerated than the 600 mg dose.

        Diabetic neuropathic pain affects about 11 million diabetics worldwide.

        The study was funded by Schwarz Pharma in Monheim, Germany.


        [Presentation title: A Multi-Center, Randomized Double-Blind, Placebo-Controlled Parallel-Group Trial to Assess the Efficacy and Safety of SPM (200, 400,and 600 mg/d) in Subjects With Painful Diabetic Neuropathy. Abstract 774]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send